Is Tazemetostat on the market?

Tazemetostat (Tazemetostat) is a methyltransferase inhibitor, which was first named EPZ-6438 in the literature. It was approved by the U.S. Food and Drug Administration ( on January 23, 2020 an>FDA) approved marketing and sold under the trade name Tazverik, which is the first to target epigenetic regulators and can specifically inhibit EZH2. This new FDA-approved oral treatment received accelerated approval for patients with hematological and solid malignancies.

Tazerestat is approved for the first time in patients 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection, based on results from an international open-label Phase II basket trial. Another open-label, multicenter Phase II trial approved the approval in patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutations who have received at least two prior systemic therapies or who have no satisfactory alternative treatment options. Tazerestat, an oral EZH2 inhibitor, offers a new effective and tolerable treatment option for these patients. The current recommended dose of tazerestat is 800 mg twice daily, with or without food, until disease progression or unacceptable toxicity occurs.

The original drug of tazerestat is not yet available in the domestic market and is therefore not included in medical insurance. Tazerestat US version of the original drug, specification200mg*240 tablets, which is marketed overseas, may cost around 200,000 yuan per bottle (the price may fluctuate due to exchange rates), which is very expensive. At present, there are no generic drugs of tazerestat produced and launched. For more drug information and specific prices, please consult the medical consultant of the drug.